Abstract
Background: In consideration of recent developments in understanding the genomics and proteomics of viruses, the use of viral DNA / RNA sequences as well as their gene expression schemes, have found new in-roads towards the prognosis and therapy of diseases. Correspondingly, the sphere of the patenting scenario has expanded significantly.
Objectives: The current review addresses patented inventions concerning the use of virus sequences as gene silencing machineries and inventions concerning the generation and application of viral sequences as expression vectors. Furthermore, this review also discusses the employment of these patents for clinical, agricultural and biotechnological applications.
Method: Considering these objectives, the Delphion Research Intellectual Property Network database was searched using keywords such as “gene silencing”, “engineered viruses” and “expression vectors” and descriptions of recent patents on the said topics were discussed.
Conclusion: Despite several recent advances in the use of viruses as disease therapy vehicles and biotechnological vectors, these developments have yet to be proven effective in practice, in clinical and field trials.
Keywords: Antisense compounds, genetically engineered viruses, expression vectors, gene-silencing, viral pathogenesis, prognosis.
Graphical Abstract
Recent Patents on Biotechnology
Title:Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles
Volume: 11 Issue: 2
Author(s): Srividhya Venkataraman*, Tauqeer Ahmad, Mounir G. AbouHaidar and Kathleen L. Hefferon
Affiliation:
- Cell and Systems Biology, University of Toronto, Toronto, ON M5G 3B2,Canada
Keywords: Antisense compounds, genetically engineered viruses, expression vectors, gene-silencing, viral pathogenesis, prognosis.
Abstract: Background: In consideration of recent developments in understanding the genomics and proteomics of viruses, the use of viral DNA / RNA sequences as well as their gene expression schemes, have found new in-roads towards the prognosis and therapy of diseases. Correspondingly, the sphere of the patenting scenario has expanded significantly.
Objectives: The current review addresses patented inventions concerning the use of virus sequences as gene silencing machineries and inventions concerning the generation and application of viral sequences as expression vectors. Furthermore, this review also discusses the employment of these patents for clinical, agricultural and biotechnological applications.
Method: Considering these objectives, the Delphion Research Intellectual Property Network database was searched using keywords such as “gene silencing”, “engineered viruses” and “expression vectors” and descriptions of recent patents on the said topics were discussed.
Conclusion: Despite several recent advances in the use of viruses as disease therapy vehicles and biotechnological vectors, these developments have yet to be proven effective in practice, in clinical and field trials.
Export Options
About this article
Cite this article as:
Venkataraman Srividhya *, Ahmad Tauqeer , AbouHaidar G. Mounir and Hefferon L. Kathleen , Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles, Recent Patents on Biotechnology 2017; 11 (2) . https://dx.doi.org/10.2174/1872208311666170301103722
DOI https://dx.doi.org/10.2174/1872208311666170301103722 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design HIV-1 Tat Protein Exposure Potentiates Ethanol Reward and Reinstates Extinguished Ethanol-Conditioned Place Preference
Current HIV Research Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Dengue: Recent Advances in Biology and Current Status of Translational Research
Current Molecular Medicine Inhibition of Viral-Induced Membrane Fusion by Peptides
Protein & Peptide Letters A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review
Current Molecular Pharmacology Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Optimization of Spotting Buffer for Polystyrene Based ELISA Arrays
Current Analytical Chemistry Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Cefepime-Induced Neurotoxicity
Central Nervous System Agents in Medicinal Chemistry Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS
Letters in Drug Design & Discovery The Causes and Consequences of Childhood Encephalitis in Asia
Infectious Disorders - Drug Targets Molecular Therapy Intervention Prospects in Prostate Cancer
Current Pharmaceutical Design Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]
Current Alzheimer Research Echinocandins for the Nursery: An Update
Current Drug Metabolism Combining Drug and Immune Therapy: A Potential Solution to Drug Resistance and Challenges of HIV Vaccines?
Current HIV Research Natural Chemical Entities as Bioactive Moiety from Weaver Ant, <i>Oecophylla smaragdina</i>: An In Vitro and In-silico Study
Letters in Drug Design & Discovery